A director at Paycom Software Inc sold 30,000 shares at 265.228USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Rocky Mountain Chocolate Factory Launches First Fully Redesigned Store in Charleston, South Carolina DURANGO, Colo., May 29, 2025 (GLOBE NEWSWIRE) -- Rocky Mountain Chocolate Factory Inc. (Nasdaq: RMCF) (the “Company”, “we”, or “RMCF”), America’s Chocolatier™ and a leading franchiser of a premium chocolate and confectionary retail store concept, is proud to announce the grand opening of its first fully redesigned store, located at 415 King Street in the heart of Charleston, South Carolina. The new location opens to the public on June 3, 2025, marking the Company’s first presence in the s...
Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution • KHINDIVI is the first and only FDA-approved hydrocortisone oral solution• Commercial launch expected the week of June 2nd• Eton expects combined peak sales of KHINDIVI and ALKINDI SPRINKLE® (hydrocortisone) oral granules to exceed $50 million DEER PARK, Ill., May 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the U.S. Foo...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Norfolk Southern Corporation and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 22 May 2025 in which we reassessed the appropriateness of the ratings in the c...
Rocky Mountain Chocolate Factory Announces Intention to File Form 12b-25 and Delay Its Fiscal Year 2025 Earnings Release and Conference Call DURANGO, Colo., May 27, 2025 (GLOBE NEWSWIRE) -- Rocky Mountain Chocolate Factory Inc. (Nasdaq: RMCF) (the “Company”, “we”, or “RMCF”), America’s Chocolatier™ and a leading franchiser of a premium chocolate and confectionary retail store concept, today announced that it intends to file a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission with regard to its annual report on Form 10-K (the “Fiscal 2025 10-K”) for the ...
The Tile Shop to Debut Exclusive Tile Collection With Nate Berkus The Tile Shop x Nate Berkus will arrive at all U.S. Tile Shop showrooms and tileshop.com starting fall 2026. MINNEAPOLIS, May 22, 2025 (GLOBE NEWSWIRE) -- The Tile Shop () today announced a new collaboration with award-winning designer Nate Berkus. The Tile Shop x Nate Berkus, available exclusively at The Tile Shop, will debut in Tile Shop showrooms and on tileshop.com in early fall 2026. The Tile Shop x Nate Berkus collection will feature floor and wall tiles, in a diverse range of materials and shapes, anchored in a pa...
Eton Pharmaceuticals to Participate at Upcoming Investor Conferences DEER PARK, Ill., May 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen, Chief Executive Officer, James Gruber, Chief Financial Officer, and David Krempa, Chief Business Officer, will participate in two upcoming investor conferences as follows: The 25th Annual B. Riley Securities Investor ConferenceDate: Thursday, May 22, 2025, at ...
Eton Pharmaceuticals Reports First Quarter 2025 Financial Results Q1 2025 revenue of $17.3 million, with product sales of $14.0 million, representing 76% growth over Q1 2024 and the 17th straight quarter of sequential product sales growthQ1 2025 basic and fully diluted GAAP EPS of $(0.06), Non-GAAP fully diluted EPS of $0.07, and Adjusted EBITDA of $3.7 millionRelaunched pediatric endocrinology biologic INCRELEX® in the U.S. and out-licensed international rightsEstablished Wilson disease franchise with the acquisition and relaunch of GALZIN® (zinc acetate) capsules and the introduction of p...
The Tile Shop Reports First Quarter 2025 Results MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- Tile Shop Holdings, Inc. (Nasdaq: TTSH) (the “Company”), a specialty retailer of natural stone, man-made and luxury vinyl tiles today announced results for its first quarter ended March 31, 2025. First Quarter 2025 Summary Net Sales Decreased 4.1%Comparable Store Sales Decreased 4.0% Gross Margin of 66.0%Net Income of $0.2 Million and Adjusted EBITDA of $4.6 MillionNo Debt Outstanding and $27.1 million of Cash at Quarter-End Management Commentary – Cabell Lolmaugh, CEO “While hou...
Lockout Rally in Full Swing Continuing the trend from last week's U.S. Macro Vision (4/29/25), we are seeing more and more signs that lead us to believe the S&P 500 (SPX) made a major bottom at 4800-4820, which is where we initially discussed in our 4/8/25 Compass to look for a local bottom to develop. As a result, we have been short-term bullish since our 4/22/25 Compass, when we noted that the SPX was testing 5100-5120 support, a potential bounce spot and a level to trade long against. With t...
The Tile Shop to Host First Quarter 2025 Earnings Conference Call MINNEAPOLIS, May 01, 2025 (GLOBE NEWSWIRE) -- Tile Shop Holdings, Inc. (Nasdaq: TTSH) (the “Company”), a specialty retailer of natural stone tiles, man-made and luxury vinyl tiles, setting and maintenance materials, and related accessories, today announced that the Company will release financial results for the first quarter ended March 31, 2025, at 7:00 a.m. Eastern Time on Thursday, May 8, 2025. The Company will host a conference call via webcast for investors and other interested parties beginning at 9:00 a.m. Eastern T...
Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025 DEER PARK, Ill., May 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2025 financial results on Tuesday, May 13, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT). Dial In* (Audio Only) Webcast: ...
Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution) - NDA submitted for the treatment of central diabetes insipidus -- Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch – DEER PARK, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ET-...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.